Retrospective Study of Long-Term Survival of Immuncell-LC in Patients Undergoing Curative Resection for HCC in Korea
A Multicenter, Retrospective Data Analysis Study on the Long-term Survival Rate of the 'Immuncell-LC Goups' and 'Non-treatment Groups' in Patient Undergo Curative Resection (PEIT, RFA or Operation) for Hepatocellular Carcinoma in Korea
Sponsor: GC Cell Corporation
Listed as NCT06620510, this observational or N/A phase trial focuses on Hepatocellular Carcinoma and remains completed. Sponsored by GC Cell Corporation, it has been updated 2 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
2 versions recorded-
Sep 2025 — Present [monthly]
Completed
Status: Not Yet Recruiting → Completed
-
Oct 2024 — Sep 2025 [monthly]
Not Yet Recruiting
First recorded
Sep 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GC Cell Corporation
For direct contact, visit the study record on ClinicalTrials.gov .